Apimeds Pharmaceuticals US, Inc. 8-K

What Happened Apimeds Pharmaceuticals US, Inc. filed an 8-K (Item 8.01) reporting that on March 31, 2026 it submitted a Form 12b-25 notifying the SEC it will be unable to timely file its Annual Report on Form 10‑K for the fiscal year ended December 31, 2025. The company said the delay is due to the continued preparation and finalization of its fourth‑quarter and year‑end financial statements and additional time needed for its independent registered public accounting firm to complete audit procedures. The company currently expects to file the Form 10‑K by April 30, 2026 but said there is no assurance it will meet that date.

Key Details

• Form 12b-25 was filed on March 31, 2026 notifying a late Form 10‑K for the fiscal year ended December 31, 2025.
• The company expects it will not be able to file within the 15‑calendar‑day extension period under SEC Rule 12b-25.
• Delay drivers: finalization of Q4 and full‑year 2025 financial statements and additional audit work by the independent registered public accounting firm.
• Apimeds expects to receive a NYSE American notice of noncompliance for the late filing and anticipates the exchange will provide a period to submit a plan to regain compliance.

Why It Matters A late Form 10‑K can affect transparency and timing of financial information investors rely on to evaluate the company. The expected NYSE American noncompliance notice may require Apimeds to submit a plan to regain compliance, which could create short‑term uncertainty for shareholders and potential impacts on trading or listing status if not resolved. The company says it is working to complete the audit and file the 10‑K, but investors should watch for the filed 10‑K and any NYSE communications for updates.